Oncimmune Holdings plc (ONC) Ordinary 1p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Oncimmune revenue falls as it implements new strategy
29 February 2024 13:04
(Sharecast News) - Oncimmune reported revenue of £2.1m in its final results on Thursday, down from £3.8m for the prior extended 15-month period, with revenue from continuing operations totalling £1.2m.
-
Oncimmune sells 'non-core' lung and antibody assets in £13m deal
22 May 2023 11:14
(Sharecast News) - Immunodiagnostics specialist Oncimmune announced the sale of its wholly-owned subsidiaries Oncimmune Limited and Oncimmune Europe to the US-based, privately-held Freenome Holdings on Monday.
-
Oncimmune enters collaboration with Siemens Healthineers
17 February 2023 15:53
(Sharecast News) - Immunodiagnostics specialist Oncimmune announced a collaboration with Siemens Healthineers on Friday, to improve malignancy risk assessment of indeterminate pulmonary nodules (IPNs).
-
Oncimmune agrees two new commercial contracts
8 April 2022 15:44
(Sharecast News) - Immunodiagnostics company Oncimmune announced the signing of two new commercial contracts for its 'ImmunoINSIGHTS' platform on Friday.
-
Oncimmune signs new contract with Alphabet division Verily
28 February 2022 14:41
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the signing of a new commercial contract with Verily Life Sciences on Monday, a member of Google owner Alphabet's stable,...
-
Oncimmune's EarlyCDT Lung test granted approval by Ministry of Health for Aragon
17 February 2022 09:09
(Sharecast News) - Immunodiagnostics group Oncimmune Holdings said on Thursday that its EarlyCDT Lung test had been granted approval by the Ministry of Health for Aragon in Spain and will now be adopted in...
-
Oncimmune reports fresh research from Cedars-Sinai Covid study
31 December 2021 11:20
(Sharecast News) - Oncimmune announced the publication of a paper arising from the research collaboration with Cedars-Sinai Medical Center in Los Angeles on Friday, focusing on the sex-specific autoimmune...
-
Oncimmune signs new commercial contracts
21 December 2021 13:07
(Sharecast News) - Oncimmune Holdings announced on Tuesday that it has signed further commercial contracts within its 'ImmunoINSIGHTS' pharma services business.
-
Oncimmune inks deal with global pharma firm
20 September 2021 11:24
(Sharecast News) - Immunodiagnostics company Oncimmune has signed an autoantibody profiling agreement with an unnamed global pharmaceutical company, it announced on Monday, to evaluate the autoantibody...
-
Oncimmune upbeat on three-year lung cancer test study
23 August 2021 15:12
(Sharecast News) - Immunodiagnostics group Oncimmune announced the pre-publication of the three-year follow-up data for the 'Early detection of Cancer of the Lung Scotland' (ECLS) trial on Monday,...
-
Oncimmune inks research deal with Dana-Farber Cancer Institute
23 July 2021 09:44
(Sharecast News) - Immunodiagnostics group Oncimmune has signed an autoantibody profiling contract with Dana-Farber Cancer Institute, based in Boston, Massachusetts, it announced on Friday.
-
Oncimmune FY revenues tracking in line with expectations
8 June 2021 10:57
(Sharecast News) - Immunodiagnostics group Oncimmune said on Tuesday that 2021 full-year revenues were in line with market expectations,
Company announcements Announcements
-
Holding(s) in Company
26 March 2024 11:18
Oncimmune Holdings
-
Block Listing Return
13 March 2024 17:32
Oncimmune Holdings
-
Posting of Notice of General Meeting
6 March 2024 15:02
Oncimmune Holdings
-
Investor Presentation via Investor Meet Company
1 March 2024 13:00
Oncimmune Holdings
-
Holding(s) in Company
29 February 2024 11:19
Oncimmune Holdings
-
Final Results
29 February 2024 07:00
Oncimmune Holdings
-
Result of AGM
26 February 2024 11:30
Oncimmune Holdings
-
Notice of AGM
2 February 2024 07:00
Oncimmune Holdings
-
Director/PDMR Shareholding
11 December 2023 15:12
Oncimmune Holdings
-
Grant of Options and PDMR Dealing
8 December 2023 14:31
Oncimmune Holdings
-
Progress against Strategy
30 November 2023 07:00
Oncimmune Holdings
-
Holding(s) in Company
10 November 2023 10:14
Oncimmune Holdings
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.